Biocon Biologics announces integration of Viatris’ Europe biosimilar business

1 Dec 2023 , 10:48 AM

Biocon Biologics, a Biocon subsidiary, stated on Thursday that the integration of Viatris’ biosimilars business in 31 European nations was completed.

Following the acquisition of substantially all of Viatris’ global biosimilar business in November 2022, and the related integration of over 70 emerging market countries in July 2023 and North America in September 2023, the company said in a release that the full transition of Viatris’ biosimilars operations to Biocon Biologics Ltd in Europe represents another significant milestone.

Biocon Biologics has seven biosimilars in its portfolio in Europe, including Insulin Aspart, Bevacizumab, Adalimumab, Pegfilgrastim, Insulin Glargine, Trastuzumab, and Etanercept.

The integration of Viatris’ biosimilar business in Europe ahead of schedule is another significant milestone for Biocon Biologics in our journey to become a global biosimilars leader, said Shreehas Tambe, CEO & MD, Biocon Biologics.

At around 10.44 AM, Biocon was trading 1.34% higher at Rs 241.50, against the previous close of Rs 238.30 on NSE. 

For feedback and suggestions, write to us at [e-mail]